Research programme: submicron respiratory disease therapeutics - iCeutica

Drug Profile

Research programme: submicron respiratory disease therapeutics - iCeutica

Alternative Names: ICE-1202; ICE-1203; ICE-1204

Latest Information Update: 03 Jun 2016

Price : $50

At a glance

  • Originator iCeutica
  • Class
  • Mechanism of Action Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Asthma; Chronic obstructive pulmonary disease; Hypersensitivity

Most Recent Events

  • 03 Jun 2016 Preclinical trials in Hypersensitivity in USA (Inhalation) (iCeutica pipeline, June 2016)
  • 01 Oct 2014 Preclinical trials in Chronic obstructive pulmonary disease in USA (Inhalation) prior to October 2014
  • 01 Oct 2014 Preclinical trials in Asthma in USA (Inhalation) prior to October 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top